| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 12th January 2021 | Morana Jovan Embiricos | 1,136,525 | Conversion of derivative | $0.00 | |
| 12th January 2021 | Morana Jovan Embiricos | 2,912,345 | Conversion of derivative | $0.00 | |
| 12th January 2021 | Morana Jovan Embiricos | 182,135 | Conversion of derivative | $0.00 | |
| 12th January 2021 | Morana Jovan Embiricos | 639,295 | Conversion of derivative | $0.00 | |
| 12th January 2021 | Morana Jovan Embiricos | 71,599 | Conversion of derivative | $0.00 | |
| 12th January 2021 | Morana Jovan Embiricos | 455,338 | Conversion of derivative | $0.00 | |
| 12th January 2021 | Morana Jovan Embiricos | 95,238 | Open or private purchase | $21.00 | $1,999,998.00 |
| 12th January 2021 | Morana Jovan Embiricos | 214,798 | Conversion of derivative | $0.00 | |
| 12th January 2021 | Morana Jovan Embiricos | 71,599 | Conversion of derivative | $0.00 | |
| 12th January 2021 | Morana Jovan Embiricos | 143,198 | Conversion of derivative | $0.00 |
Tcr2 Therapeutics
TCR2 Therapeutics, Inc. is an immunotherapy company. It develops biological drugs and engineering T-cells for cancer therapy. The company was founded in May 2015 and is headquartered in Cambridge, MA.
Ticker: TCRR
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1750019
Employees: 83
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $50 M (0%)
Assets, Current: $134 M (-18%)
Property, Plant and Equipment, Net: $6 M (0%)
Assets: $140 M (-16%)
Accounts Payable, Current: $3 M (20%)
Accrued Liabilities, Current: $3 M (0%)
Liabilities, Current: $6 M (-15%)
Other Liabilities, Noncurrent: $609 Th (11%)
Liabilities: $7 M (-13%)
Common Stock, Value, Issued: $2 Th (0%)
Common Stock, Shares, Issued: $24 M (0%)
Additional Paid in Capital, Common Stock: $347 M (1%)
Retained Earnings (Accumulated Deficit): $214 M (17%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $402 Th (183%)
Stockholders' Equity (Parent): $133 M (0%)
Liabilities and Equity: $140 M (-16%)
Research and Development: $13 M (-48%)
General and Administrative Expenses: $4 M (-52%)
Operating Income/Loss: $17 M (-49%)
Other Income, net: $499 Th (-59%)
Provision for income taxes: $28 Th (-49%)
News
TCR² Therapeutics Announces Proposed Public Offering of Common Stock
19th January 2021
TCR² Therapeutics to Present at J.P. Morgan Healthcare Conference
21st December 2020